Abstract
The frequency of peripheral blood cells expressing the perforin gene or the granzyme B gene was evaluated by in situ hybridization in nine patients suffering from metastatic melanoma and treated with recombinant interleukin-2 (rIL-2). A spontaneous expression of both genes was detected in five to seven patients, rIL-2 administration increased the frequency of positive cells in all patients (P<0.03 for each gene), the highest frequency being reached in the patients who already expressed these genes prior to rIL-2 treatment (P<0.02). Expressions of the granzyme B gene and of the perforin gene were strongly correlated before IL-2 treatment and they were similarly affected by rIL-2 administration. In contrast, their modification under treatment did not correlate with that of CD56+ cell counts, of natural killer activity and of sCD8 release. This indicates that perforin and granzyme B gene expressions are markers of cytotoxic cell activation independent of those previously described, and that they should be further evaluated in patients with malignancies to delineate their potential value in predicting clinical outcome.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Barth RJ, Mulé JJ, Spiess PJ, Rosenberg SA (1991) Inteferon γ and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes. J Exp Med 173: 647
Clément MV, Haddad P, Soulié A, Benvenuti C, Lichtenheld MG, Podack ER, Sigaux N, Sasportes M (1991) Perforin and granzyme B as markers for acute rejection in heart transplantation. Int Immunol 3: 1175
Crowley NJ, Slingluff CL, Darrow TL, Siegler HF (1990) Generation of human autologous melanoma specific cytotoxic T-cells using HLA-A2 matched allogenic melanomas. Cancer Res 50: 492
Devergne O, Peuchmaur M, Crevon MC, Trapani JA, Maillot MC, Galanaud P, Emilie D (1991) Activation of cytotoxic cells in hyperplastic lymph nodes from HIV-infected patients. AIDS 5: 1071
Golstein P, Ojcius DM, Young JDE (1991) Cell mediated death mechanisms and the immune system. Immunol Rev 121: 29
Griffiths GM, Mueller C (1991) Expression of perforin and granzymes in vivo: potential diagnosis markers for activated cytotoxic cells. Immunol Today 12: 415
Hensel JW, Wesselschmidt RL, Ley TJ (1993) Generation of mice deficient in the cytotoxic lymphocyte serine protease granzyme B (abstract 958). Blood 82 [Suppl]: 243a
Hock H, Dorsch M, Kunzendorf U, Qin Z, Diamantstein T, Blankenstein T (1993) Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon γ. Proc Natl Acad Sci USA 90: 2774
Humbert M, Devergne O, Cerrina J, Rain B, Simonneau G, Dartevelle P, Duroux P, Galanaud P, Emilie D (1992) Activation of macrophages and cytotoxic cells during cytomegalovirus pneumonia complicating lung transplantations. Am Rev Respir Dis 145: 1178
Kast WM, Offringa R, Peters PJ, Voordouw AC, Meloen RH, Eb AJ van der, Melief CJM (1989) Eradication of adenovirus El-induced tumors by EIA-specific cytotoxic T lymphocytes. Cell 59: 603
Kriegler M, Perez C, De Fay K, Albert I, Lu D (1988) A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell 53: 45
Léger-Ravet MB, Devergne O, Peuchmaur M, Solal-Celigny P, Brousse N, Gaulard P, Galanaud P, Emilie D (1994) In situ detection of activated cytotoxic cells in follicular lymphomas. Am J Pathol 144: 492
Legha SS (1989) Current therapy for melanoma. Semin Oncol 16: 34
Lim SH, Worman C, Jewell A, Tsakona C, Giles FJ, Goldstone A (1991) Lymphocyte activation and serine-esterase induction following recombinant interleukin-2 infusion for lymphomas and acute leukemias. Cancer Immunol Immunother 32: 133
Liu CC, Rafii S, Granelli-Piperno A, Trapani JA, Young JDE (1989) Perforin and serine esterase gene expression in stimulated human T cells. Kinetics, mitogen requirements, and effects of cyclosporin A. J Exp Med 170: 2105
Manyak CL, Norton GP, Lobe CG, Bleackley RC, Gershengeld HK, Weissman IL, Kumar V, Sial NH, Koo GC (1989) IL-2 induces expression of serine protease enzymes and genes in natural killer and non specific T killer cells. J Immunol 142: 3707
Mc Clay EF, Mastrangelo MJ, Spandio JR (1989) The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma. Cancer 63: 1292
Nishanian P, Hofmann B, Wang Y, Jackson AL, Detels R, Fahey JL (1991) Serum soluble CD8 molecule is a marker of CD8 T-cell activation in HIV-1 disease. AIDS 5: 805
Parmiani G, Anichini A, Fossati G (1990) Cellular immune response against autologous human malignant melanoma: are in vitro studies providing a frame work for a more effective immunotherapy. J Natl Cancer Inst 82: 361
Peuchmaur M, Emilie D, Crevon MC, Solal-Celigny P, Maillot MC, Lemaigre G, Galanaud P (1990) IL-2 mRNA expression of Tac-positive malignant lymphomas. Am J Pathol 136: 383
Peuchmaur M, Emilie D, Crevon MC, Brousse N, Gaulard P, Agay MF d', Galanaud P, Solal-Celigny P (1991) Interleukin-2 and interferon-gamma production in follicular lymphomas. Am J Clin Pathol 95: 55
Ratner A, Clark WR (1993) Role of TNF-α CD8+ cytotoxic T lymphocyte-mediated lysis. J Immunol 150: 4303
Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan M, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med 316: 889–897
Smyth MJ, Ortaldo JR, Shinkai Y-I, Yagita H, Nakata M, Okomura K, Young HA (1990) Interleukin 2 induction of pore-forming protein gene expression in human peripheral blood CD8+ T cells. J Exp Med 171: 1269
Tian Q, Streuli M, Saito H, Schlossman SF, Anderson P (1991) A polyadenylate binding protein localized to the granules of cytotoxic lymphocytes induces DNA fragmentation in target cells. Cell 67: 629
Tolédano M, Mathiot C, Michon J, Andreu G, Lando D, Brandely M, Fridman WH (1989) Interferon-γ (IFNγ) and interleukin-2 in the generation of lymphokine-activated killer cytotoxicity. IFNγ-induced suppressive activity. Cancer Immunol Immunother 30: 57
Tschopp J, Nabholz M (1990) Perforin-mediated target cell lysis by cytolytic T lymphocytes. Annu Rev Immunol 8: 279
Waal M de, Verma S, Berajano MT, Ranes-Goldberg M, Hill M, Spits H (1993) CD2/LFA-3 or LFA-1/ICAM-1 but not CD28/B7 interactions can augment cytotoxicity by virus-specific CD8+ cytotoxic T lymphocytes. Eur J Immunol 23: 418
West WH, Tauer KW, Yanelli JR, Marshall GD, Orr DW, Thurman GB, Oldham RK (1987) Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316: 898
Yander Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van Den Eynde B, Knuth A, Boon T (1989) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Leger-Ravet, MB., Mathiot, C., Portier, A. et al. Increased expression of perforin and granzyme B genes in patients with metastatic melanoma treated with recombinant interleukin-2. Cancer Immunol Immunother 39, 53–58 (1994). https://doi.org/10.1007/BF01517181
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01517181